Taken together, these findings support the role of FAP as a marker of tumor aggressiveness, risk stratification and therapeutic response, and warrant further investigation into its integration into routine pathological assessment and clinical decision-making in ccRCC. This evidence concerns the gene FAP and nonpapillary renal cell carcinoma.